InvestWiser

Zelluna ASA

ZLNAOslo BørsHealthcareMarket value 461 m NOK
15.45NOK +1.6%
last day · Price as of 19 November 2026

The answer first

Does Zelluna beat the market?

Yes, Zelluna has beaten the market over the last year.

Zelluna+75.6%Oslo Børs (OSEBX)+30.6%
  • The ranking · Quality, value and trend combined

    Better than 40% of Nordic stocks

    • Quality99
    • Value2
    • Trend40

    No. 79 of 195 in healthcare

Max for seven days

Follow Zelluna with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Zelluna

From today, at a price of 15.45 NOK. Write why you follow Zelluna, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Zelluna

Your first answer is free, no account needed.

Do you own Zelluna, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Zelluna and a few more. Free, no card.

Past year against the exchange and Super Stock
Zelluna+75.6%Oslo Børs (OSEBX)+30.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Zelluna has risen 75.6% over the past year, including dividends.
  • Overall, Zelluna ranks better than 40% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.5%. The price is 99.0% below its peak now.

Who owns Zelluna? See the major shareholders and their stakes

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

40

Quality, value and trend together. Better than 40% of Nordic stocks.

No. 79 of 195 in healthcare

Quality99
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 3 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.01
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−128.5%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 183 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity5.3
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend40
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 90 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−26.8%
  • 6 months−29.1%
  • 9 months−2.8%
  • 12 months+75.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−16.3%
3 years, per year
−74.5%
5 years, per year
−58.4%
Year to date
+12.0%
Largest fall, 3 years
−99.5%
From a peak to the bottom
From the peak now
−99.0%
How far the price is from the peak
Volatility, 1 year
72.4%
How much the price swings over a year
Beta, 1 year
0.38
How much the price moves when the market moves

Return with dividends reinvested.

About Zelluna

Zelluna ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 15 employees.

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

See the full analysis of Zelluna.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market